OSE Immuno: recruitment completed for UC trial
The randomized, double-blind, placebo-controlled Phase 2 CoTikiS study is evaluating the efficacy and safety of Lusvertikimab versus placebo in patients with moderate-to-severe active UC who are treatment-naive or who have failed, lost response or intolerance to prior treatment(s).
An interim futility analysis was successfully conducted on the first 50 patients (33% of the total number of patients planned in the study) to complete the induction phase of the trial.
The first post-induction efficacy results (primary endpoint at week 10) and a first assessment after 6 months of treatment in the open-label extension phase are expected in the coming months (mid-2024).
Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, commented: "We are very pleased to have completed enrolment in the Phase 2 trial evaluating Lusvertikimab in ulcerative colitis, a major milestone for the Company and the development of the product. We now look forward to the top-line results of this efficacy trial over the next 6 months to confirm Lusvertikimab's potential as an innovative first-in-class treatment option in this chronic and debilitating inflammatory bowel disease. Positive clinical efficacy results for Lusvertikimab in ulcerative colitis in mid-2024 could also act as a strong catalyst in the coming months, boosting OSE's presence in the growing field of chronic inflammation.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction